Exact Sciences Corporation (EXAS) Stock
EXAS Key Statistics
About Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
CEO: Kevin T. Conroy. Company website
EXAS — Frequently Asked Questions
What is the EXAS stock price today?
Exact Sciences Corporation (EXAS) trades at $104.91, up 0.00% on the day, as of Nov 12, 2026 09:20 UTC.
What is Exact Sciences Corporation's market cap?
Exact Sciences Corporation has a market capitalisation of $20.03B, calculated from the live EXAS share price and shares outstanding.
What is the P/E ratio of EXAS?
EXAS has no meaningful price-to-earnings ratio: Exact Sciences Corporation lost $1.10 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Exact Sciences Corporation make?
Exact Sciences Corporation generated revenue of $3.25B over the trailing twelve months, which puts the stock at 6.17 times sales.
What is the 52-week range for EXAS?
EXAS has traded between $64.92 and $104.98 over the past 52 weeks, and the last price is 0.1% below that high.
Is Exact Sciences Corporation profitable?
No. Exact Sciences Corporation is loss-making, with a net margin of -6.40% over the trailing twelve months.
What is the analyst price target for EXAS?
Wall Street analysts rate EXAS Buy, with an average price target of $103.18, 1.6% below the current price.
What sector is Exact Sciences Corporation in?
Exact Sciences Corporation is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US .
Who is the CEO of Exact Sciences Corporation?
Kevin T. Conroy is the chief executive of Exact Sciences Corporation, which employs 6,900 people.
Where can I track EXAS in real time?
QFI Terminal shows EXAS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See EXAS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open EXAS in Terminal See plans